Peptide Policy Shifts: RFK Jr. Pushes FDA Deregulation While Biohacking Booms

In the past 48 hours, the biohacking industry faces headwinds from biotech's broader struggles, with pricing pressures and rising costs compressing drug development returns, as highlighted in a April ...

23 Huhti 2min

In the past 48 hours, the biohacking industry shows steady momentum driven by 2026 consumer trends toward energy optimization and natural longevity hacks, with no major market disruptions or regulator...

22 Huhti 2min

Biohacking Industry Current State Analysis Past 48 HoursIn the past 48 hours, the biohacking industry shows robust momentum driven by health tech surges and regulatory wins, with Hims and Hers Health ...

21 Huhti 2min

In the past 48 hours as of April 20, 2026, the biohacking industry shows surging momentum driven by peptide therapies and longevity trends, with no major market disruptions but clear signs of mainstre...

20 Huhti 2min

In the past 48 hours, the biohacking industry shows a surging global boom, particularly in Japan where the movement is exploding as of April 2026, driving demand for devices like the Hatch Restore 2 s...

17 Huhti 1min

In the past 48 hours, the biohacking industry shows steady momentum amid rising consumer interest in affordable longevity solutions. Mitolyn, a mitochondria-focused supplement targeting cellular energ...

16 Huhti 2min

In the past 48 hours, the biohacking industry shows limited major movements, with activity centered on supplement and audio-based cognitive enhancement products amid steady consumer interest in nootro...

15 Huhti 2min

In the past 48 hours, the biohacking industry shows steady momentum in longevity biotech, with no major disruptions but growing institutional investment and product buzz. Global R&D spending on longev...

14 Huhti 2min